RemAb is developing a pipeline with different indications. Our most advanced program aims to provide immediate protection to patients admitted to Intensive Care Units (ICU) without generating antimicrobial resistance (AMR).
RemAb Therapeutics is a spin‐off of Bellvitge Biomedical Research Institute (IDIBELL), based in Barcelona.
Antimicrobial resistance (AMR) is a growing global threat to human health and economic development.
RA-01 is novel drug product and a first line therapy for preventing nosocomial infections at ICUs.
CaixaImpulse program
July / 2016
Ref.: CI16-00037
Fons de Patents Gínjol Program
GAS-1: 2017 – 3rd edition
GAS: 2016 - 1st edition
